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Abstract 
Merkel cell carcinoma (MCC) is an uncom-
mon cutaneous malignant tumor that presents
as  a  rapidly  growing  skin  nodule  on  sun-
exposed areas of the body. MCC is aggressive
with regional nodal and distant metastases to
the skin, lung, and bones. There have been no
reports of metastatic MCC to the mesentery
and  6  reports  describing  metastasis  to  the
small intestine. We present a case of metasta-
tic MCC to the mesentery with infiltration to
the small bowel, 8 years after original tumor
resection.  This  is  the  5
th metastasis  and  it
encased the small bowel resulting in a hair-pin
loop contributing to the unusual clinical pres-
entation.  Although  MCC  metastatic  to  the
bowel is uncommon, it is not rare. It is impor-
tant to recognize the unusual manifestations
of  this  disease  as  they  are  becoming  more
common in the future. Routine radiologic sur-
veillance and thorough review of systems are
important to patient follow-up.
Introduction
Merkel  cell  carcinoma  of  the  skin  (MCC)
was first described by Toker
1 in 1972. It is a
rare,  aggressive  cutaneous  malignancy  that
predominantly affects elderly Caucasians and
immunocompromised  populations.  The  inci-
dence  of  MCC  has  increased  in  the  last  15
years, yet its pathogenesis is still debated.
2,3
Ultraviolet radiation,
2,4,5 immunosuppression,
4,7
and a novel polyomavirus
6 have been implicat-
ed as important etiologic agents. The clinical
presentation of MCC is nonspecific, with the
majority of cases presenting as a rapidly grow-
ing,  painless,  firm,  shiny,  flesh-colored  to
bluish-red,  intracutaneous  nodule  on  a  sun-
exposed  surface  of  the  body.  Histologically,
MCC usually arises in the dermis and extends
into  the  subcutis  with  infrequent  epidermal
involvement. The differential of this small blue
cell tumor includes other poorly differentiated
neoplastic tumors such as small cell carcinoma
of the lung, lymphoma, metastatic carcinoid,
amelanotic  melanoma  and  Ewing  sarcoma.
MCC is defined by both neuroendocrine and
epithelial differentiation as demonstrated by
immunopositivity  for  perinuclear  cytokeratin
20  expression  and  neuroendocrine  markers
like chromogranin and synaptophysin. The dis-
ease course is difficult to predict and ranges
from relatively indolent to highly aggressive,
with a propensity for local recurrence, region-
al lymph node metastases as well as metastasis
to  distant  sites.  Overall,  the  prognosis  for
patients with MCC is poor with 5-year survival
rates  of  ~75%,  59%,  and  25%  for  localized,
regional,  and  distant  MCC,  respectively.
Metastasis usually occurs in the skin, lymph
nodes,  liver,  lung,  bone,  and  the  brain.
Metastasis can also involve the gastrointesti-
nal tract in sporadic cases. Due to the rarity of
the  disease,  there  are  no  randomized  treat-
ment trials for MCC, hence no standardized
treatment exists. At present, treatment options
include surgery alone or with adjuvant radia-
tion  therapy,  and  systemic  chemotherapy
reserved  for  recurrent  or  disseminated  dis-
ease. Earlier detection of this neoplasm with
multidisciplinary management may achieve a
better prognosis and an improved outcome as
demonstrated by the following case.
Clinical features and histologic
findings
The patient is a 73-year old Caucasian man
with a past medical history most significant for
coronary artery disease, hypertension, and dia-
betes  mellitus  who  presented  with  a  raised,
violacious skin lesion of the middle third of his
left  radial  forearm  in  December  of  2001.  A
punch biopsy at an outside institution revealed
MCC. A 2.0 cm wide local excision of the biop-
sy scar and tumor bed was performed along
with  sentinel  lymph  node  biopsy  of  the  left
epitrochlear and left axillary basins. The mar-
gins were widely negative, as were all four sen-
tinel nodes. The patient was treated postoper-
atively with adjuvant radiation to the primary
site and 4 cycles of carboplatin and etoposide.
One year after surgery, a follow-up CT scan
of the chest, abdomen, and pelvis was within
normal limits. However, a CT scan of the chest
in May of 2003 revealed a large, 5.6¥4.2 cm left
axillary mass along with an adjacent 1.9¥1.8
cm mass (Figure 1A). Fine needle aspiration of
the  larger  mass  was  positive  for  metastatic
MCC. With no evidence of distant metastases,
the patient underwent a level III left axillary
lymph node dissection. Histologic examination
showed  metastatic  MCC  to  four  of  twenty
(4/20)  discrete  and  matted  lymph  nodes.
Microscopically, the normal lymph node archi-
tecture had been replaced by a population of
monotonous, round tumor cells with frequent
apoptotic  nuclei  and  mitotic  figures.  These
cells had scant eosinophilic cytoplasm as well
as round and vesicular nuclei with finely gran-
ular chromatin and multiple nucleoli. Adjuvant
radiation therapy was administered to the axil-
la,  and  the  patient  was  followed  at  regular
intervals. In October of 2003, the patient devel-
oped a 1.4¥1.2¥0.6 cm left anterior chest wall
mass at the margin of his radiation port, which
again was confirmed to be MCC on fine needle
aspiration. He underwent a wide local excision
of the left anterior chest wall and the left infe-
rior axilla. The margins of resection were neg-
ative, and the patient again received postoper-
ative radiation therapy, this time to the chest
wall and mediastinum, with concurrent taxol-
based chemotherapy.
The  patient  was  followed  every  6  months
with  pelvic  and  abdominal  CT  scans.  These
tests were unremarkable until April of 2007,
when he presented with a 6.0¥5.6¥4.5 cm right
anterior chest wall mass deep to the pectoralis
muscle. Fine needle aspiration of the mass was
positive for metastatic MCC. The patient was
taken to the operating room for a fourth time
for  radical  resection  of  the  right  chest  wall
mass with en bloc resection of the pectoralis
major and minor muscles. Histologic examina-
tion demonstrated metastatic MCC to one of
two (1/2) lymph nodes with negative deep and
peripheral  margins.  Postoperatively,  the
patient received additional adjuvant radiation
Rare Tumors 2011; volume 3:e2
Correspondence: Jeffrey D. Wayne, Department
of  Surgery;  Feinberg  School  of  Medicine,
Northwestern  University  676  North  St.  Clair
Street, Suite 650 Chicago, IL 60611, USA.
E-mail: jwayne@northwestern.edu
Key  words:  Merkel  cell  carcinoma,  mesentery,
small intestine, metastasis, Cytokeratin 20.
Contributions: KAM, writing of manuscript and
compilation  of  figures;  AH,  medical  care  of
patient and writing of manuscript; JGL, medical
care of patient and writing of manuscript; G-YY,
assistance  with  figures  and  review  of  manu-
script; TMK, medical care of patient and review of
manuscript;  JDW,  medical  care  of  patient  and
review of manuscript.
Received for publication: 7 December 2010.
Accepted for publication: 16 December 2010.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright K.A. Matkowskyj et al., 2011
Licensee PAGEPress, Italy
Rare Tumors 2011; 3:e2
doi:10.4081/rt.2011.e2[Rare Tumors 2011; 3:e2] [page 5]
therapy.  PET  imaging  in  November  of  2007
showed increased metabolic activity in 2 sites:
the mid-right anterolateral chest wall and in
the  lower  left  anterolateral  abdominal  wall
near the anterior iliac spine. Radical resection
of two soft tissue masses was performed with
abdominal reconstruction using Prolene mesh.
Postoperative  histologic  examination  con-
firmed both masses to be metastatic MCC with
negative margins.
In May of 2009, the patient presented with
intermittent, crampy abdominal pain associat-
ed  with  decreased  appetite  and  a  15  pound
weight  loss.  A  CT  scan  of  the  abdomen
revealed a new, enhancing lesion encasing the
distal  jejunum  and  proximal  ileum  (Figure
1B).  The  patient  underwent  laparoscopic-
assisted jejunal resection. On gross examina-
tion,  the  small  bowel  was  remarkable  for  a
10.5¥9.5¥8.0 cm lobulated mesenteric tumor
forming a hair-pin loop in the bowel (Figure
2A). Microscopically, there was an infiltrate of
small  blue  neoplastic  cells  undermining  the
mucosa  (Figure  2B).  The  morphology  and
cytology of these tumor cells was identical to
that previously identified in the lymph node
(Figure 2C). In addition, perinuclear dot-like
expression of CK20 (Figure 2D) confirmed the
diagnosis of MCC metastatic to the mesentery
and small bowel. All resection margins were
free of tumor. The patient was discharged after
an uneventful, three-day hospital stay.
Discussion
MCC is an uncommon skin cancer of neu-
roendocrine origin effecting primarily elderly
Caucasians  which  has  a  high  rate  of  local
recurrence  and  regional  metastases  first
described  by  Toker  in  1972.
1 Despite  being
rare, the incidence of MCC has tripled over the
last 15 years with nearly 1,200 new cases diag-
nosed in the US each year.
2,3 The pathogenesis
of MCC is not fully understood. MCC is thought
to arise from Merkel cells that are located in
the basal layer of the epidermis, however the
majority of MCCs are intradermal and only 10%
arise in the epidermis. In addition, several fac-
tors such as ultraviolet (UV) radiation expo-
sure,
2,4,5 Merkel  cell  polyomavirus,
6 and
immuno  suppression
4,7 have  been  associated
with the development of MCC.
The classic initial presentation of MCC is a
painless,  indurated,  solitary  dermal  nodule
with a slightly erythematous to deeply viola-
ceous color, on sun-exposed areas of the body.
Because  of  the  benign,  nonspecific  clinical
appearance of the initial lesion, MCC is rarely
suspected prior to biopsy. The majority of pri-
mary MCC lesions occur in the head and neck
region, but a large proportion also involve the
extremities.
1,3 MCC arises in the dermis, can
extend into the subcutaneous tissue, and can
infiltrate locally via dermal lymphatics, result-
ing in multiple satellite lesions. Metastasis is
most common to the distant lymph nodes and
skin, lung, central nervous system and bone, in
order of decreasing frequency.
5 As spread of
MCC occurs via lymphatic drainage, nodal sta-
tus appears to be the strongest predictor of dis-
tant metastases.
8
Metastasis to the mesenteric soft tissue has
not been reported and metastasis to the bowel
being  extremely  rare,  with  only  six  cases
described  to  date.  Naunton  Morgan  et  al.
reported the first case in 1985 of a 42-year-old
man with an MCC skin lesion on his right shin
which first metastasized to his right femoral
Case Report
Figure 1. Preoperative computed tomography scans of the patients metastatic lesions.  A
scan from May 2003 demonstrates a 5.6 cm lobulated mass (white arrow) in the left axil-
la (A). In May 2009, a CT scan reveals a short segment of circumferential mural thick-
ening of the jejunum and an eccentric, contiguous 4.3 cm serosal-based mass (arrow)
with no evidence of bowel obstruction (B). 
Figure 2. Macroscopic and histologic appearance of metastatic Merkel cell carcinoma.  In
May 2009, the patient complained of vague abdominal pain and was found to have a 6.5
cm mesenteric mass involving the jejunum and ileum and resulting in a hair-pin loop
(A). Low power (B; H&E, x20) and high power (C; H&E, x200) microscopic examina-
tion demonstrates the small intestinal wall is infiltrated by small, blue neoplastic cells
focally involving the mucosa. There is a monotonous population of small, loosely cohe-
sive tumor cells. The cells have round to oval nuclei, well-defined nuclear membranes,
finely granular chromatin with inconspicuous nucleoli, scanty eosinophilic cytoplasm
and frequent apoptotic nuclei and mitotic figures. Immunohistochemistry performed on
the tumor mass shows dot-like perinuclear expression of cytokeratin 20 in the neoplas-
tic cells, confirming the diagnosis of metastatic Merkel cell carcinoma (D; CK20, x200).[page 6] [Rare Tumors 2011; 3:e2]
lymph nodes.
9 The patient later presented with
melena and anemia. A barium follow-through
study  revealed  a  stricture  of  the  proximal
jejunum caused by a 6.5¥5¥4 cm tumor which
was found to be metastatic MCC. Canales et al.
encountered a case of metastatic MCC to the
stomach and duodenum from a right buttock
lesion.
10 Foster et al. reported a male with MCC
of the right cheek which spread to the small
bowel, as well as to the right lung, right adre-
nal gland, and left perirenal space.
11 Shalhub et
al. described a 62 year old man who presented
with  right  axillary  and  left  groin  lym-
phadenopathy and a colonic mass consistent
with  metastatic  MCC.  The  patient’s  primary
neck lesion had been excised 6 years earlier.
One  month  after  presentation,  the  patient
developed metastasis to his stomach, duode-
num, and right hip.
12 In 2007, Hizawa et al.
described the case of a woman with MCC of the
right  eyelid  who  presented  with  an  intra-
abdominal mass directly invading the stomach,
pancreas, and distal duodenum.
13 Most recent-
ly, Cheung et al. described the case of a woman
who presented with a 2 cm lesion in the right
antecubital fossa followed by metastatic MCC
to the ileocecal valve 18 months after initial
diagnosis.
14
Due to the rarity of the disease, there have
been no randomized trials for the treatment of
MCC and current therapies are based on obser-
vational studies alone. At presentation, 60-75%
of patients with MCC have only local disease,
10-25% have regional lymph node involvement
and 2-8% have metastatic disease.
5,15 Although
metastasis is uncommon at presentation, ~33-
50%  of  patients  with  MCC  will  eventually
develop systemic metastasis.
5 Due to the high
propensity for local recurrence and metastasis,
MCC has been cited as having an overall 5-year
survival rate of ~60% with only 50% of patients
with advanced disease alive at 9 months. The
disparity in survival is most likely due to early
detection,  aggressive  treatment  and  a  shift
from  monotherapy  to  a  multidisciplinary
approach. Outcomes are correlated with loca-
tion and size of the primary lesion, regional
metastasis,  gender  and  age.
2,16 However,
despite  improvements  in  survival,  optimal
treatment  of  MCC  has  yet  to  be  well  estab-
lished.  Currently,  surgical  treatment  centers
on  margin-negative  excision  of  the  primary
tumor.
15,16 Surgical staging with sentinel lymph
node biopsy has also been shown to be impor-
tant, as up to one-third of patients with clini-
cally  negative  lymph  nodes  had  lymph  node
metastases.
17 Adjuvant radiation therapy also
plays a significant role in MCC treatment by
reducing  recurrence  and  improving  local/
regional control of disease.
3,15,18 Thus, for local-
ized disease, surgical excision with adjuvant
radiotherapy  is  recommended,  achieving  a
local control rate of 60-90%. Treatment of dis-
tant  metastases  involves  palliative  surgery,
radiotherapy,  and  chemotherapy.  Despite  its
use, the role of chemotherapy remains contro-
versial  because  MCC  has  been  found  to  be
chemosensitive,  but  chemotherapy  rarely
results in a cure. Close radiologic follow-up is
recommended for patients with MCC due to
the high recurrence rate even with aggressive
therapy. Nuclear studies are used for sentinel
lymph node biopsy for initial staging of MCC,
and  positron  emission  tomography  (PET)
imaging  is  helpful  in  monitoring  treatment
response and recurrence.
In conclusion, we report a case of MCC with
metastases found in five separate sites despite
aggressive surgical treatment combined with
adjuvant  radiation  and  chemotherapy.  The
most recent metastasis was to the mesentery
with infiltration of the small bowel, which is a
very rare site of MCC spread. Therefore, it is
important to recognize metastatic MCC as a
potential  source  of  abdominal  symptoms  in
patients  with  a  previous  diagnosis  of  MCC.
Additionally,  this  case  highlights  the  malig-
nant nature of MCC and emphasizes the need
for  close  follow-up  despite  aggressive  treat-
ment.
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